Multiple asset management and investment firms have adjusted their holdings in Regeneron Pharmaceuticals (REGN). Wedge Capital Management, Vanguard, and Amova Asset Management reduced their stake, while firms like Global X Japan Co. Ltd., Nordea Investment Management, and Hamilton Wealth LLC increased their holdings. Despite some firms reducing their ownership, the overall sentiment about the pharmaceutical company is largely positive, with notable recognition of its strong performance, valuable advancements, and further potential for growth.
Regeneron's Dupixent received approval in Japan for treating Bullous Pemphigoid, making the Bull Case stronger for REGN. Meanwhile, positive trials results were reported from REGN's advancements in Obesity Phase 3 and Allergy Pipeline.
Despite fluctuations and recent pullbacks, Regeneron's valuation and share price momentum remain promising, as signified by the 28.9% spike in six months, outlook for the next 10 years, and 60% upside prediction.
Analysts also seem bullish on the stock with a consensus recommendation of “Moderate Buy”. Other significant updates include REGN's Q4 earnings beat and positive forecast for 2026 and plans of releasing its quarterly results on April 29.
Regeneron Pharmaceuticals REGN News Analytics from Wed, 13 Aug 2025 07:00:00 GMT to Sat, 28 Mar 2026 12:24:32 GMT - Rating 7 - Innovation 8 - Information 8 - Rumor 3
